Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

PainSolve: we aspire to solve pain



PainSolve is a research focused community for all those interested in tackling the burden of pain.

By facilitating collaboration, we aim to increase disease understanding and co-develop new solutions for patients with pain.

Join our community today to unlock members-only areas, and to participate in future initiatives such as webinars and discussion forums to share knowledge.

PainSpectrum: Visit the PainSpectrum to interact with our
innovative body map of almost 100 pain conditions.

Priorities in Pain: Understand the patient and physician

Updates: Stay up to date with analysis on the latest research

Why we care

Chronic pain is a burden suffered by millions worldwide.
Its effects are complex and far-reaching, leaving patients and their families often without effective therapy – feeling helpless.

PainSolve is a research community for all those interested in tackling the burden of chronic pain.
It is a resource and platform for pain research; together, we want to better understand pain and work towards better pain solutions.

We are openly sharing our extensive knowledge in several areas of pain.
This includes our interactive body map of almost 100 pain conditions.

Register now to access a downloadable pain module library and case studies in niche pain conditions

Gabriel Baertschi Chief Executive Officer (CEO) Grünenthal Group

Gabriel Baertschi, Chairman of the Corporate Executive Board, Chief Executive Officer

“Pain is not a symptom: It's a disease in its own right and needs to be addressed with innovative treatments. At Grünenthal, we want to join forces with you to make a genuine difference in the life of patients affected by pain”

Gabriel Baertschi

Chairman of the Corporate Executive Board, Chief Executive Officer

Surveys and Webinars

Placebo Effect and Pain – Part 3

In this latest article on the placebo effect and pain, we look at the findings from a recently published trial supported by Grünenthal that shows promise for reducing the likelihood of clinical trial failure due to variations and bias in symptom reporting by participants. The background to this study and its implications are discussed.

... Discover more

IMI-PainCare Initiative

The Innovative Medicines Initiative (IMI) PainCare initiative is a consortium composed of 40 participants from 14 countries, co-led by Grünenthal and the University of Heidelberg. The three sub-projects, PROMPT, BioPain and TRiPP, aim to revolutionise different aspects of pain research and development, and pain management with the aim of improving the care of patients suffering from acute or chronic pain.

... Discover more

CGRP Antibodies in Migraine

Calcitonin gene-related peptide (CGRP)-targeted antibodies represent the first in a new class of drugs designed for the preventive treatment of migraine in adults. Following the recent FDA approval in this drug group, we review the pathophysiology of migraine and how these novel treatments can revolutionise prevention of this debilitating condition.

... Discover more


Share this with:

These are external links and will open in a new window